Promotion of early cancer detection

A major reason why pancreatic is so deadly can be attributed to late detection when the cancer has become advanced and is no longer amenable to surgery. There are currently no good biomarkers that can be used for early detection.

As part of a larger consortium (Circulating Biomarker Consortium for Pancreatic Cancer Early Detection, NIH U01CA210171 grant), we are working on a number of projects to address this problem, for example, by evaluating circulating tumor DNA (ctDNA) mutations and methylation patterns, circulating cancer-derived exosomes, and metabolism markers. The goal is to identify individuals at risk early on for disease screening.

Comments are closed.